LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

Inicio・Lista de Acciones・Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals Inc

Cerrado

1.1 -1.79

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

1.07

Máximo

1.1400000000000001

Métricas clave
By Trading Economics
Ingresos	1.7M -5.1M
Ventas	90K 90K
Margen de beneficio	-5,701.111
Empleados	25
EBITDA	2.6M -4.9M

Dividendos
By Dow Jones
Próximas Ganancias	27 mar 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	-6.9M 35M
Apertura anterior	2.89
Cierre anterior	1.1

Actinium Pharmaceuticals Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

18 mar 2026, 22:51 UTC

Ganancias

AIA Group Value of New Business Rose in 2025, Plans $1.7 Billion New Share Buyback

18 mar 2026, 21:40 UTC

Adquisiciones, fusiones, absorciones

Constellation Energy to Sell Portfolio of Assets for $5 Billion to Satisfy Regulators

18 mar 2026, 20:31 UTC

Ganancias

Micron 2Q Sales Nearly Triple Amid Tight Memory Supply

18 mar 2026, 23:49 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Nikkei May Fall on Renewed Concerns About Higher Energy Prices -- Market Talk

18 mar 2026, 23:31 UTC

Charlas de Mercado

Gold Rises on Likely Technical Recovery -- Market Talk

18 mar 2026, 22:49 UTC

Charlas de Mercado

New Zealand's Economic Recovery Has Yet to Find Footing -- Market Talk

18 mar 2026, 22:41 UTC

Charlas de Mercado

Woodside Energy Opts for 'Safe, Experienced' Choice as CEO -- Market Talk

18 mar 2026, 22:36 UTC

Ganancias

AIA Group Value of New Business Rose in 2025, Plans $1.7B New Share Buyback

18 mar 2026, 22:24 UTC

Ganancias

AIA Group Announces New Share Buyback of $1.7B >1299.HK

18 mar 2026, 22:23 UTC

Ganancias

AIA Group 2025 Value of New Business Margin Was 58.5%, Up 3.6 Ppt on Year >1299.HK

18 mar 2026, 22:23 UTC

Ganancias

AIA Group 2025 Value of New Business $5.52B Vs. $4.71B >1299.HK

18 mar 2026, 21:58 UTC

Ganancias

Micron Sales Nearly Triple Amid Tight Memory Supply -- Update

18 mar 2026, 21:55 UTC

Charlas de Mercado

Ganancias

Global Equities Roundup: Market Talk

18 mar 2026, 21:55 UTC

Charlas de Mercado

Ganancias

Micron's Phone, PC Business Could Shrink Due to Memory Shortage -- Market Talk

18 mar 2026, 21:40 UTC

Charlas de Mercado

Fuel Price Rise Equates to 20 Bps Rate Hike on Australian Households -- Market Talk

18 mar 2026, 21:16 UTC

Charlas de Mercado

More Procter & Gamble Alumni Join Strobel at Coty -- Market Talk

18 mar 2026, 21:00 UTC

Noticias de Eventos Importantes

Iran War Puts Pressure on Japan's Economy. Takaichi Is In a Bind. -- Barrons.com

18 mar 2026, 20:58 UTC

Ganancias

Micron 2Q Gross Margin Nearly Doubled Due to Higher Pricing, CFO Says

18 mar 2026, 20:41 UTC

Ganancias

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

18 mar 2026, 20:29 UTC

Ganancias

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

18 mar 2026, 20:25 UTC

Ganancias

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

18 mar 2026, 20:17 UTC

Ganancias

These Stocks Are Today's Movers: Micron, Swarmer, Lumentum, Trade Desk, Macy's, Williams-Sonoma, and More -- Barrons.com

18 mar 2026, 20:14 UTC

Charlas de Mercado

Airlines Can't Offset Higher Fuel Prices for Long -- Market Talk

18 mar 2026, 20:09 UTC

Ganancias

Micron Reports Extraordinary Earnings. The Stock Is Up. -- Barrons.com

18 mar 2026, 20:07 UTC

Ganancias

Micron Technology Raises Qtr Dividend to 15c Vs. 11.5c >MU

18 mar 2026, 20:06 UTC

Ganancias

Micron Technology Board Has Approved 30% Increase in Qtrly Div >MU

18 mar 2026, 20:04 UTC

Ganancias

Micron Technology 2Q Operating Cash Flow $11.9 B >MU

18 mar 2026, 20:04 UTC

Ganancias

Micron Technology Sees 3Q Operating Expenses About $1.6 B >MU

18 mar 2026, 20:04 UTC

Ganancias

Micron Technology Sees 3Q Gross Margin About 81% >MU

18 mar 2026, 20:03 UTC

Ganancias

Micron Technology Sees 3Q Adj EPS $19.15 +/- 40c >MU

Comparación entre iguales

Cambio de precio

Actinium Pharmaceuticals Inc Esperado

Consenso

By TipRanks

0 ratings

Comprar

Mantener

Vender

De acuerdo con 0 analistas que ofrecen calificaciones bursátiles a para Actinium Pharmaceuticals Inc Dist en los últimos 3 meses.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.